Pharma and Biotech Daily: Navigating Uncertainty in the Industry

Pharma and BioTech Daily

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Robert F. Kennedy Jr., known for his anti-vaccine views, has been chosen by President Trump to lead the Department of Health and Human Services. Kennedy has expressed plans to overhaul the FDA and reduce the NIH's headcount, raising concerns about the future of healthcare regulation. In other news, Celgene shareholders are suing Bristol-Myers Squibb for allegedly avoiding contingent value right payments related to their acquisition deal, while Eyenovia's stock plummets after dropping their lead program due to lack of efficacy. Bluebird Bio is facing a cash shortage with only two quarters of funding left, prompting executives to seek financing to reach breakeven point by 2025. Overall, the pharmaceutical industry had a tumultuous third quarter, with companies like Gilead and Kite cutting employees and closing sites. The industry is in a state of uncertainty as it navigates through these challenges.